Spruce Biosciences Inc. (SPRB) announced that it has priced a public offering expected to raise $60 million in gross proceeds to advance its neurological disorder therapies.
The late-stage biopharma will sell 1.15 million common shares at $50.00 each.
Certain investors will instead receive pre-funded warrants to buy 50,000 shares at $49.99, reflecting the offer price minus $0.01 exercise price.
The offering is set to close on April 22.
Underwriters have a 30-day option to purchase up to 180,000 additional shares.
On the Nasdaq, shares of Spruce Biosciences were losing 12.15 percent in overnight trading at $61.40, after closing Monday's regular trading 0.58 percent lower at $69.90
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.